Delivering New Hope to Prevent Cancer Recurrence in Breast Cancer Patients

Recruiting · Phase 2 · Breast Cancer and related conditions · California, Illinois, Massachusetts, Pennsylvania and Tennessee

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how two medicines, atezolizumab and sacituzumab govitecan, work together to help prevent cancer from coming back in patients with triple negative breast cancer. The goal is to see if this combination is effective for patients who still have some cancer after treatment. Participants will receive treatment for 18 weeks and be followed for three years to monitor their progress.

The trial's ID number is NCT04434040. It is a Phase 2 study, which means it is testing how well the treatment works and how safe it is. The FDA regulates this study, and about 40 participants are expected to join.

Who can join

This trial is open to men and women aged 18 and older. To join, participants must have confirmed residual breast cancer after receiving chemotherapy. They should also have specific test results related to hormone receptors and HER2 status. Additionally, participants need to show evidence of cancer DNA in their blood after their initial treatments. The trial team will confirm who can join.

Conditions

Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in the study will receive the combination of atezolizumab and sacituzumab govitecan. Treatment will last for 18 weeks, given over six cycles. Atezolizumab will be given through an IV on day 1 of each cycle, while sacituzumab govitecan will be given on days 1 and 8 of each cycle. Participants will regularly visit the clinic for follow-ups.